Halozyme Therapeutics, Inc. logo HALO - Halozyme Therapeutics, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY
0
BUY 17
HOLD 9
SELL 1
STRONG
SELL
0
| PRICE TARGET: $88.25 DETAILS
HIGH: $95.00
LOW: $75.00
MEDIAN: $91.50
CONSENSUS: $88.25
UPSIDE: 9.61%
AlphaQuality

AlphaQuality

Quantitative six-pillar business-quality grade

Platform & Compounding FCF

AlphaQuality — archetype-weighted quantitative grade

A- 80.0 / 100 composite

Composite Grade

Composite of six pillars weighted for platform & compounding fcf businesses. Purely quantitative — no stock price or analyst input.

Profitability

Weight: 25%
B 71.3
  • 5yr Avg ROIC 12.1% 70/100
  • Operating Margin Trend +0.62 pp/yr 74/100
Contributes 17.8 pts toward composite.

Capital Efficiency

Weight: 15%
A+ 99.3
  • 5yr Avg ROE 675.0% 100/100
  • 5yr Share-Count CAGR -4.1% 98/100
Contributes 14.9 pts toward composite.

Growth Quality

Weight: 25%
B 70.8
  • 5yr Revenue CAGR 33.2% 100/100
  • 5yr EPS CAGR -1.7% 17/100
  • Revenue-Growth Years (5) 5/5 100/100
Contributes 17.7 pts toward composite.

Cash Generation

Weight: 20%
A+ 98.0
  • 5yr FCF Margin 48.0% 100/100
  • 5yr FCF/NI Conversion 1.26x 96/100
Contributes 19.6 pts toward composite.

Balance Sheet

Weight: 10%
B 71.7
  • Net Debt / EBITDA 3.49x 40/100
  • Interest Coverage (EBIT/Int) 26.76x 100/100
  • Altman Z-Score 3.97 95/100
Contributes 7.2 pts toward composite.

Stability

Weight: 5%
C 56.8
  • EPS Volatility (σ/μ) 0.55 26/100
  • Piotroski F-Score 6 67/100
  • Negative-Revenue Years (5) 0/5 100/100
Contributes 2.8 pts toward composite.

Guru Flow

Curated superinvestor sentiment — not part of the AlphaQuality grade.
Trimming

3 of 3 gurus held; 1 added; 2 trimmed.

Holders
3
Avg Δ position
-12.6%
New buys
0
Full exits
0
As of Q1 2026
How this is calculated

AlphaQuality grades six pillars from 0-100 and weights each by archetype:

  • Profitability (25%) — 5yr Avg ROIC, Operating Margin Trend
  • Capital Efficiency (15%) — 5yr Avg ROE, 5yr Share-Count CAGR
  • Growth Quality (25%) — 5yr Revenue CAGR, 5yr EPS CAGR, Revenue-Growth Years (5)
  • Cash Generation (20%) — 5yr FCF Margin, 5yr FCF/NI Conversion
  • Balance Sheet (10%) — Net Debt / EBITDA, Interest Coverage (EBIT/Int), Altman Z-Score
  • Stability (5%) — EPS Volatility (σ/μ), Piotroski F-Score, Negative-Revenue Years (5)

We deliberately ignore stock price, analyst targets, and consensus ratings so the grade is suitable for backtesting forward returns. A minimum of 5 fiscal years of audited statements is required; distressed and highly leveraged infrastructure businesses are declared ungradable rather than forced into a numeric score.